Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIPK2 | Q9H2X6 | 9/20 | 0.62 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 4/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 3/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25616187 | 0.83 | HIPK2 (0.59) | HIPK2LMNAKMT2ATDP1CSNK2A1 | |
| SCHEMBL25616240 | 0.83 | HIPK2 (0.59) | HIPK2LMNAKMT2ATDP1SLC6A2 | |
| SCHEMBL20718341 | 0.83 | HIPK2 (0.59) | HIPK2LMNAKMT2ATDP1SLC6A2 | |
| SCHEMBL25616191 | 0.83 | KMT2A (0.52) | HIPK2LMNAKMT2ATDP1SLC6A2 | |
| SCHEMBL25616214 | 0.82 | HIPK2 (0.65) | HIPK2LMNAKMT2ATDP1CSNK2A1 | |
| SCHEMBL25616221 | 0.82 | HIPK2 (0.65) | HIPK2LMNAKMT2ATDP1CSNK2A1 | |
| SCHEMBL20718401 | 0.81 | HIPK2 (0.77) | HIPK2CSNK2A1CSNK2A2CSNK2B | |
| SCHEMBL25616231 | 0.81 | HIPK2 (0.66) | HIPK2LMNAKMT2ATDP1CSNK2A1 | |
| SCHEMBL25616248 | 0.80 | HIPK2 (0.61) | HIPK2LMNAKMT2ATDP1SLC6A2 | |
| SCHEMBL20718340 | 0.80 | LMNA (0.56) | HIPK2LMNAKMT2ATDP1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-06-22 | — | — | US | disclosed |
| WO-2019028059-A1 | ANTI-CANCER/ANTI-FIBROSIS COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192621-A1 | Anti-Cancer/Anti-Fibrosis Compounds | CCL11, MMP1, HDGF | HIPK2 2797/4885LMNA 2370/4885KMT2A 2904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.